Niagen Bioscience (NAGE) Price & Analysis

Compare

602 Followers

NAGE Stock Chart & Stats

$6.86

Market closed

$6.86

Day’s Range― - ―

52-Week Range$5.16 - $14.69

Previous CloseN/A

VolumeN/A

Average Volume (3M)1.12M

Market Cap

$548.27M

Enterprise Value$746.92M

Total Cash (Recent Filing)$64.14M

Total Debt (Recent Filing)$3.06M

Price to Earnings (P/E)28.5

Beta0.89

Next Earnings

Mar 11, 2026

EPS Estimate

0.02

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.05

Shares Outstanding79,806,140

10 Day Avg. Volume1,216,723

30 Day Avg. Volume1,121,085

Financial Highlights & Ratios

PEG Ratio-0.22

Price to Book (P/B)9.84

Price to Sales (P/S)4.55

P/FCF Ratio37.97

Enterprise Value/Market Cap1.36

Enterprise Value/Revenue5.99

Enterprise Value/Gross Profit9.37

Enterprise Value/Ebitda35.33

Forecast

1Y Price Target

$16.33

Price Target Upside138.05% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering3

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Financial PerformanceNiagen Bioscience delivered encouraging financial results, reporting top-line revenue totaling $34M vs. forecast of only $31.5M.

Market ExpansionThe addition of Tru Niagen Beauty helps expand Niagen's total addressable market and allows the company to participate in the fast-growing 'internal beauty' category in the US.

Product LaunchNiagen announced the launch of Tru Niagen Beauty in the US, building on the Tru Niagen franchise and focusing on internal beauty with clinically-studied ingredients for skin, nail, and hair health.

Bears Say

Clinical Data UncertaintyUnfavorable clinical data could pose risks to Niagen's market position.

Competitive PressureThe FDA decision that NMN can be used in supplements could lead to more NMN products and increased competition for Niagen Bioscience.

Sales Growth RiskRisks include slower-than-projected U.S. sales growth.

Niagen Bioscience News

Niagen Bioscience announces results of Niagen supplementation in long COVID

Niagen Bioscience (NAGE) shared promising results from the first-of-its-kind clinical trial published today in The Lancet peer-reviewed journal...

7d ago

NAGE

Niagen Bioscience announces $10M share repurchase program

Niagen Bioscience (NAGE) announced that its board of directors has approved a share repurchase program under which the...

13d ago

NAGE

Niagen Bioscience price target lowered to $14 from $16 at Canaccord

Canaccord lowered the firm’s price target on Niagen Bioscience (NAGE) to $14 from $16 and keeps a Buy...

15d ago

NAGE

Niagen Bioscience reports Q3 EPS 5c vs 2c last year

Reports Q3 revenue $33.986M, consensus $31.1M. “We delivered another strong performance with third quarter net sales of $34.0...

15d ago

NAGE

Niagen Bioscience reiterates FY25 net sales growth view of 25%-30%

For the full year, the Company reiterated its recently revised top-line guidance of 25% to 30% year-over-year net...

15d ago

NAGE

Meet Niagen Bioscience: Fly exclusive interview with CFO Ozan Pamir

In an exclusive interview, Niagen Bioscience’s (NAGE) CFO Ozan Pamir met with The Fly to discuss the company, the biotech...

25d ago

NAGE

Meet Niagen Bioscience: Fly exclusive interview with CFO Ozan Pamir

In an exclusive interview, Niagen Bioscience’s (NAGE) CFO Ozan Pamir met with The Fly to discuss the company, the biotech...

27d ago

NAGE

Niagen CFO Pamir says ‘very much focused’ on profitability

14:00 EDT Niagen CFO Pamir says ‘very much focused’ on profitability Published first on TheFly – the ultimate...

27d ago

NAGE

Niagen growing fast, financial health a priority, CFO tells The Fly

14:00 EDT Niagen growing fast, financial health a priority, CFO tells The Fly Published first on TheFly –...

27d ago

NAGE

Niagen CFO expects Parkinson’s trial results in early 2026

14:00 EDT Niagen CFO expects Parkinson’s trial results in early 2026 Published first on TheFly – the ultimate...

27d ago

NAGE

Niagen Bioscience Announces $10 Million Share Buyback

Niagen Bioscience ( ($NAGE) ) has provided an announcement. On November 6, 2025, Niagen Bioscience announced that its...

14d ago

NAGE

ChromaDex Reports Record Growth Amid Strategic Expansions

ChromaDex Corporation (($NAGE)) has held its Q3 earnings call. Read on for the main highlights of the call....

14d ago

NAGE

Niagen Bioscience Reports Strong Q3 2025 Results

ChromaDex Corporation ( ($NAGE) ) has released its Q3 earnings. Here is a breakdown of the information ChromaDex...

15d ago

NAGE

Niagen Bioscience Reports 33% Q3 Sales Increase

Niagen Bioscience ( ($NAGE) ) has issued an announcement. On November 4, 2025, Niagen Bioscience reported a 33%...

15d ago

NAGE

NAGE FAQ

What was Niagen Bioscience’s price range in the past 12 months?

Niagen Bioscience lowest stock price was $5.16 and its highest was $14.69 in the past 12 months.

What is Niagen Bioscience’s market cap?

Niagen Bioscience’s market cap is $548.27M.

When is Niagen Bioscience’s upcoming earnings report date?

Niagen Bioscience’s upcoming earnings report date is Mar 11, 2026 which is in 111 days.

How were Niagen Bioscience’s earnings last quarter?

Niagen Bioscience released its earnings results on Nov 04, 2025. The company reported $0.05 earnings per share for the quarter, beating the consensus estimate of $0.018 by $0.032.

Is Niagen Bioscience overvalued?

According to Wall Street analysts Niagen Bioscience’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Niagen Bioscience pay dividends?

Niagen Bioscience does not currently pay dividends.

What is Niagen Bioscience’s EPS estimate?

Niagen Bioscience’s EPS estimate is 0.02.

How many shares outstanding does Niagen Bioscience have?

Niagen Bioscience has 79,806,140 shares outstanding.

What happened to Niagen Bioscience’s price movement after its last earnings report?

Niagen Bioscience reported an EPS of $0.05 in its last earnings report, beating expectations of $0.018. Following the earnings report the stock price went down -1.007%.

Which hedge fund is a major shareholder of Niagen Bioscience?

Currently, no hedge funds are holding shares in NAGE

Niagen Bioscience Stock Smart Score

Outperform

Fundamentals

Return on Equity

38.90%

Trailing 12-Months

Asset Growth

73.63%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Niagen Bioscience

Niagen Bioscience Inc is a bioscience company dedicated to healthy aging. The Company leads research on nicotinamide adenine dinucleotide.

Niagen Bioscience (NAGE) Earnings & Revenues

Historic Earnings Reports

NAGE Company Deck

NAGE Earnings Call

Q3 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call presented a strong performance with record revenue growth and strategic expansions. However, challenges remain in regulatory environments and pricing strategies in certain markets.View all NAGE earnings summaries

NAGE Stock 12 Month Forecast

Average Price Target

$16.33

▲(138.05% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","13":"$13","24":"$24","7.5":"$7.5","18.5":"$18.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":23,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$23.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16.33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$16.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$12.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,7.5,13,18.5,24],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.54,8.72923076923077,9.918461538461539,11.107692307692307,12.296923076923077,13.486153846153847,14.675384615384615,15.864615384615384,17.053846153846155,18.243076923076924,19.432307692307692,20.621538461538464,21.810769230769232,{"y":23,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.54,8.216153846153846,8.892307692307693,9.568461538461538,10.244615384615384,10.920769230769231,11.596923076923076,12.273076923076923,12.94923076923077,13.625384615384615,14.30153846153846,14.977692307692308,15.653846153846153,{"y":16.33,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.54,7.883076923076923,8.226153846153846,8.569230769230769,8.912307692307692,9.255384615384616,9.598461538461539,9.94153846153846,10.284615384615385,10.627692307692307,10.97076923076923,11.313846153846153,11.656923076923077,{"y":12,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.56,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.86,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.56,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.3,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.64,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.87,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.56,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.73,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.81,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.04,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.88,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.89,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.54,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >